Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Identifieur interne : 002485 ( PubMed/Checkpoint ); précédent : 002484; suivant : 002486Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Auteurs : Susann Junghanns [Allemagne] ; Joerg T. Fuhrmann ; Gregor Simonis ; Christian Oelwein ; Rainer Koch ; Ruth H. Strasser ; Heinz Reichmann ; Alexander StorchSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Benzothiazoles (therapeutic use), Dopamine Agonists (therapeutic use), Double-Blind Method, Echocardiography (instrumentation), Ergolines (therapeutic use), Female, Fibrosis (epidemiology), Fibrosis (pathology), Heart Valve Diseases (diagnosis), Heart Valve Diseases (epidemiology), Heart Valve Diseases (pathology), Humans, Hypertrophy, Left Ventricular (diagnosis), Hypertrophy, Left Ventricular (epidemiology), Indoles (therapeutic use), Male, Middle Aged, Mitral Valve Insufficiency (diagnosis), Mitral Valve Insufficiency (epidemiology), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Pergolide (therapeutic use), Severity of Illness Index, Tricuspid Valve Insufficiency (diagnosis), Tricuspid Valve Insufficiency (epidemiology).
- MESH :
- chemical , therapeutic use : Benzothiazoles, Dopamine Agonists, Ergolines, Indoles, Pergolide.
- diagnosis : Heart Valve Diseases, Hypertrophy, Left Ventricular, Mitral Valve Insufficiency, Tricuspid Valve Insufficiency.
- drug therapy : Parkinson Disease.
- epidemiology : Fibrosis, Heart Valve Diseases, Hypertrophy, Left Ventricular, Mitral Valve Insufficiency, Parkinson Disease, Tricuspid Valve Insufficiency.
- instrumentation : Echocardiography.
- pathology : Fibrosis, Heart Valve Diseases.
- Double-Blind Method, Female, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non-ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinirole, pramipexole) on morphology and function of heart valves in patients with Parkinson's disease (PD) to determine the frequency and clinical relevance of DA-induced VHD. A total of 85 patients treated with ergot or non-ergot DAs and 38 age-matched controls were evaluated by transthoracic echocardiography. Valvular pathology was assessed by established criteria of valvular regurgitation and a VHD scoring system. Both grading systems revealed increased frequency of VHD in ergot DA patients compared to both non-ergot DA patients and controls with 22% of ergot DA patients having moderate VHD versus 3% of non-ergot DA patients and none of controls (P = 0.001). We did not find correlations of echocardiographic findings with duration/cumulative dose of treatment, age, or vascular risk factors. Our data suggest that ergot DAs are associated with higher prevalence of VHD compared to non-ergot DAs and controls. Standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs.
DOI: 10.1002/mds.21225
PubMed: 17094087
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17094087Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.</title><author><name sortKey="Junghanns, Susann" sort="Junghanns, Susann" uniqKey="Junghanns S" first="Susann" last="Junghanns">Susann Junghanns</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Technical University of Dresden, Dresden</wicri:regionArea><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name></author><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name></author><author><name sortKey="Oelwein, Christian" sort="Oelwein, Christian" uniqKey="Oelwein C" first="Christian" last="Oelwein">Christian Oelwein</name></author><author><name sortKey="Koch, Rainer" sort="Koch, Rainer" uniqKey="Koch R" first="Rainer" last="Koch">Rainer Koch</name></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21225</idno><idno type="RBID">pubmed:17094087</idno><idno type="pmid">17094087</idno><idno type="wicri:Area/PubMed/Corpus">002990</idno><idno type="wicri:Area/PubMed/Curation">002990</idno><idno type="wicri:Area/PubMed/Checkpoint">002485</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.</title><author><name sortKey="Junghanns, Susann" sort="Junghanns, Susann" uniqKey="Junghanns S" first="Susann" last="Junghanns">Susann Junghanns</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Technical University of Dresden, Dresden</wicri:regionArea><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name></author><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name></author><author><name sortKey="Oelwein, Christian" sort="Oelwein, Christian" uniqKey="Oelwein C" first="Christian" last="Oelwein">Christian Oelwein</name></author><author><name sortKey="Koch, Rainer" sort="Koch, Rainer" uniqKey="Koch R" first="Rainer" last="Koch">Rainer Koch</name></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzothiazoles (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Double-Blind Method</term><term>Echocardiography (instrumentation)</term><term>Ergolines (therapeutic use)</term><term>Female</term><term>Fibrosis (epidemiology)</term><term>Fibrosis (pathology)</term><term>Heart Valve Diseases (diagnosis)</term><term>Heart Valve Diseases (epidemiology)</term><term>Heart Valve Diseases (pathology)</term><term>Humans</term><term>Hypertrophy, Left Ventricular (diagnosis)</term><term>Hypertrophy, Left Ventricular (epidemiology)</term><term>Indoles (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Mitral Valve Insufficiency (diagnosis)</term><term>Mitral Valve Insufficiency (epidemiology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Pergolide (therapeutic use)</term><term>Severity of Illness Index</term><term>Tricuspid Valve Insufficiency (diagnosis)</term><term>Tricuspid Valve Insufficiency (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Indoles</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Heart Valve Diseases</term><term>Hypertrophy, Left Ventricular</term><term>Mitral Valve Insufficiency</term><term>Tricuspid Valve Insufficiency</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Fibrosis</term><term>Heart Valve Diseases</term><term>Hypertrophy, Left Ventricular</term><term>Mitral Valve Insufficiency</term><term>Parkinson Disease</term><term>Tricuspid Valve Insufficiency</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Echocardiography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Fibrosis</term><term>Heart Valve Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non-ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinirole, pramipexole) on morphology and function of heart valves in patients with Parkinson's disease (PD) to determine the frequency and clinical relevance of DA-induced VHD. A total of 85 patients treated with ergot or non-ergot DAs and 38 age-matched controls were evaluated by transthoracic echocardiography. Valvular pathology was assessed by established criteria of valvular regurgitation and a VHD scoring system. Both grading systems revealed increased frequency of VHD in ergot DA patients compared to both non-ergot DA patients and controls with 22% of ergot DA patients having moderate VHD versus 3% of non-ergot DA patients and none of controls (P = 0.001). We did not find correlations of echocardiographic findings with duration/cumulative dose of treatment, age, or vascular risk factors. Our data suggest that ergot DAs are associated with higher prevalence of VHD compared to non-ergot DAs and controls. Standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17094087</PMID><DateCreated><Year>2007</Year><Month>02</Month><Day>05</Day></DateCreated><DateCompleted><Year>2007</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.</ArticleTitle><Pagination><MedlinePgn>234-8</MedlinePgn></Pagination><Abstract><AbstractText>Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non-ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinirole, pramipexole) on morphology and function of heart valves in patients with Parkinson's disease (PD) to determine the frequency and clinical relevance of DA-induced VHD. A total of 85 patients treated with ergot or non-ergot DAs and 38 age-matched controls were evaluated by transthoracic echocardiography. Valvular pathology was assessed by established criteria of valvular regurgitation and a VHD scoring system. Both grading systems revealed increased frequency of VHD in ergot DA patients compared to both non-ergot DA patients and controls with 22% of ergot DA patients having moderate VHD versus 3% of non-ergot DA patients and none of controls (P = 0.001). We did not find correlations of echocardiographic findings with duration/cumulative dose of treatment, age, or vascular risk factors. Our data suggest that ergot DAs are associated with higher prevalence of VHD compared to non-ergot DAs and controls. Standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Junghanns</LastName><ForeName>Susann</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technical University of Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>Joerg T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Simonis</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Oelwein</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Strasser</LastName><ForeName>Ruth H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Reichmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Storch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004873">Ergolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber><NameOfSubstance UI="D010479">Pergolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="C061333">pramipexole</NameOfSubstance></Chemical><Chemical><RegistryNumber>LL60K9J05T</RegistryNumber><NameOfSubstance UI="C047047">cabergoline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D052160">Benzothiazoles</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004452">Echocardiography</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005355">Fibrosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006349">Heart Valve Diseases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017379">Hypertrophy, Left Ventricular</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008944">Mitral Valve Insufficiency</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014262">Tricuspid Valve Insufficiency</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21225</ArticleId><ArticleId IdType="pubmed">17094087</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>District de Dresde</li><li>Saxe (Land)</li></region><settlement><li>Dresde</li></settlement></list><tree><noCountry><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name><name sortKey="Koch, Rainer" sort="Koch, Rainer" uniqKey="Koch R" first="Rainer" last="Koch">Rainer Koch</name><name sortKey="Oelwein, Christian" sort="Oelwein, Christian" uniqKey="Oelwein C" first="Christian" last="Oelwein">Christian Oelwein</name><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></noCountry><country name="Allemagne"><region name="Saxe (Land)"><name sortKey="Junghanns, Susann" sort="Junghanns, Susann" uniqKey="Junghanns S" first="Susann" last="Junghanns">Susann Junghanns</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002485 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002485 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17094087
|texte= Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17094087" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |